Navigation Links
Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
Date:7/11/2013

ESTERO, Fla., July 11, 2013 /PRNewswire/ -- On May 16, 2013, United States District Court for the Eastern District of North Carolina DISMISSED with prejudice all claims for copyright and patent infringement asserted by plaintiffs Cornerstone BioPharma, Inc. ("Cornerstone") and J-Med Pharmaceuticals, Inc. ("J-Med") against Vision Pharma, LLC ("Vision"), Sander Busman, Thomas DeStefano, and Michael McAloose.  The dismissal followed the decision of the United States Court of Appeals for the Federal Circuit, upholding the USPTO Board of Patent Appeals and Interferences' rejection of U.S. Patent No. 6,270,796, the sole patent asserted in the case. See In re J-Med Pharmaceuticals, Inc., No. 11-1415 (Fed. Cir.).  On January 11, 2013, the USPTO issued an Ex Parte Reexamination Certificate cancelling all claims of the '796 Patent.

"We were very confident from the absolute beginning that Vision, Thomas DeStefano, Michael McAloose and I would receive a most favorable outcome regarding Cornerstone and J-Med's case against us.  Although these results are especially pleasing, this decision should not have taken so long to happen," said Sander S. Busman, Founder, President & CEO, Vision Pharma. Vision Pharma was represented by Ben Pleune and David Alban of Alston & Bird, LLP. 

About Vision Pharma

Vision Pharma specializes in niche, generic pharmaceuticals with various delivery options and dosage forms.  The company provides quality products at competitive prices while improving the lives of those who take their medicines. The organization's customer service acts promptly to requests while continuously improving to fulfill each customer and patient need. Maintaining additional inventory ensures Vision's ability to provide increased service levels. The pipeline of generic pharmaceuticals planned to market continues to be a strong focus internally and with other pharmaceutical organizations, domestically and internationally. Valuable relationships that are built show true dedication to each partnering company. You can count on Vision Pharma to consider the patient's safety as a top priority when developing and manufacturing their items. To learn more, please visit www.visionpharma.com.

Media Relations Contact:
Sander S. Busman
Vision Pharma
Founder, President & CEO
sbusman@visionpharma.com

 

 


'/>"/>
SOURCE Vision Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
2. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
4. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
5. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
6. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Argus Announces Next Generation Pharmacy Claims Processing Solution
9. American Association for Homecare Expects Medicare to Move Past its Deny-at-All-Costs Culture that Routinely Denies Claims for Power Wheelchairs
10. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
11. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... measurement of corrosive ions found in power plant water and steam. , Chlorides ... as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... offered by the American Association of Integrative Medicine and available for application on ... at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco ... blog post about women’s hair loss. Although hair transplant procedures can be seen as ... Menopause or genetics can be two reasons a woman may see her hair thinning. ...
Breaking Medicine News(10 mins):